Close Menu

Pacific Biosciences

The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million. 

Oxford Nanopore filed two lawsuits, one in the UK and one in Germany.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.  

PacBio recently launched a new sequencing chemistry for Sequel that increases read lengths, and plans to double the platform's throughput by the end of the year.

Pacific Biosciences nearly doubled its product and services revenue due to sales of its Sequel instrument.

The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 25-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.